Brief: Palatin Announces Positive Topline Results From Phase 2 Ulcerative Colitis (UC) Study Of Oral Melanocortin-1 Receptor Agonist Pl8177
28/03/2025 11:49
March 28 (Reuters) - Palatin Technologies Inc PTN.A: PALATIN ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 ULCERATIVE COLITIS (UC) STUDY OF ORAL MELANOCORTIN-1 RECEPTOR AGONIST PL8177 PALATIN: CLINICAL REMISSION ACHIEVED IN 33% OF PL8177-TREATED PATIENTS VERSUS 0% ON PLACEBO AFTER EIGHT WEEKS OF TREATMENT PALATIN TECHNOLOGIES INC: SAFETY AND TOLERABILITY: EXCELLENT, WITH NO ADVERSE EVENTS PALATIN: STATISTICALLY SIGNIFICANT CLINICAL RESPONSE SEEN IN 78% OF PL8177-TREATED PATIENTS VERSUS 33% ON PLACEBO AFTER 8 WEEKS OF TREATMENT Source text: ID:nPn4BYDMga Further company coverage: PTN.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity